QINGDAO -- In November, AstraZeneca, a global pharmaceutical company headquartered in Britain, announced the opening of a regional headquarters for rare diseases in Qingdao, east China's Shandong Province.
The groundbreaking ceremony of AstraZeneca pMDI inhalation manufacture site was held in Qingdao, and the construction of the AstraZeneca pMDI Inhalation Manufacture Site already started with a planned investment of 3.1 billion yuan (about 453 million U.S. dollars).
AstraZeneca has also established regional headquarters in Beijing, Hangzhou, Chengdu, Guangzhou and Wuxi, and upgraded its research and development platform in Shanghai to a global research and development center.
"We are very optimistic about China, regarding it as a manufacturing center and an indispensable part of the supply chain," said Wang Lei, global executive vice president of AstraZeneca.